Aslan, Burcu
Kismali, Gorkem
Iles, Lakesla R.
Manyam, Ganiraju C.
Ayres, Mary L.
Chen, Lisa S. http://orcid.org/0000-0001-8020-3438
Gagea, Mihai
Bertilaccio, Maria Teresa Sabrina
Wierda, William G. http://orcid.org/0000-0002-7357-270X
Gandhi, Varsha http://orcid.org/0000-0002-3172-9166
Funding for this research was provided by:
UT | University of Texas MD Anderson Cancer Center (CLL MoonShot)
Article History
Received: 14 February 2022
Accepted: 27 April 2022
First Online: 20 May 2022
Competing interests
: Specifically, for the current investigations, VG received sponsored research agreement from Loxo Oncology (now a subsidiary of Lilly Oncology). Previously, for other investigations, VG received research funding from Pharmacyclics, Acerta, Gilead Sciences, Sunesis, Infinity, AbbVie, and Clear Creek Bio. WGW received research funding from GSK/Novartis, AbbVie, Genentech, Pharmacyclics, AstraZeneca/Acerta Pharma, Gilead Sciences, Juno Therapeutics, KITE Pharma, Sunesis, Miragen, Oncternal Therapeutics, Cyclacel, Loxo Oncology, Janssen, and Xencor. The remaining authors declare no competing financial interests.